DiagnoCure Retains JMP to Help with Lab Business

The company's president noted that his firm and JMP Securities will work together to "determine the most effective method to roll out our colorectal cancer disease management program."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.